Pharmacokinetic Properties of Amikacin in Asian Neonates and Infants: A Narrative Review.
DOI:
https://doi.org/10.70672/arzefb84Keywords:
Amikacin, Asian, Neonates, PharmacokineticAbstract
Amikacin (AMK) is among the narrow therapeutic index drugs that are still being used in neonates for early-onset and late-onset sepsis. The pharmacokinetic and pharmacodynamic properties of drugs in neonates vary across ages, especially in premature babies. Neonates exhibit differences in body composition and organ function, which can influence drug disposition and response. Although much literature has discussed the pharmacokinetics of AMK in neonates, this review aims to explore the pharmacokinetic properties of AMK in Asian neonates and infants. Seven articles were included in this review, with evaluation conducted on Malaysian, Japanese, Pakistani, Indian, Korean, and Thai neonates. Overall, 702 neonates were included in these studies, consisting of both preterm and term neonates, with one study focusing exclusively on low-birth-weight neonates. This review highlights that a high dose of AMK with once-daily dosing shows a better option for achieving therapeutic concentrations. Nevertheless, variability in pharmacokinetic profiles across neonatal age was observed. Factors affecting these pharmacokinetic changes need to be addressed during the initiation of AMK therapy in neonates to ensure optimal outcomes.
References
[1]. Sizar O, Rahman S, Sundareshan V. Amikacin [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430908/
[2]. Committee CPW. Clinical Pharmacokinetics Pharmacy Handbook Second Edition. 2 ed. Pharmacy Practice and Development Division: Ministry of Health Malaysia; 2019.
[3]. An SH, Kim JY, Gwak HS. Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. American Journal of Health-System Pharmacy. 2014 Jan 15;71(2):122–7.
[4]. Yusof NN, Alias NM, Nik Saffian NNN, Mustafa S, Azmi NL. A Retrospective Study of Amikacin Dosage Adequacy Based on Therapeutic Drug Monitoring in Neonates in a Tertiary Care Hospital in Kelantan, Malaysia. Asian Journal of Medicine and Health Sciences [Internet]. 2024 Jun;7(1):65–76. Available from: https://myjurnal.mohe.gov.my/public/article-view.php?id=214821
[5]. Pomanong Aramwit, Pavich Tongroach, Chanokporn Boonthanksir. Pharmacokinetics of amikacin in premature neonates at Pramongkutklao Hospital. Chulalongkorn Medical Journal [Internet]. 2008;52(1). Available from: https://he05.tci-thaijo.org/index.php/CMJ/article/view/1004
[6]. Endo A, Kazumi Hanawa, Nemoto A, Ishikawa T, Kazama S, Kagami Y, et al. Evaluation of nephrotoxicity and ototoxicity following amikacin administration once daily or every 48 hours in neonates. Medicine (Baltimore, Md) [Internet]. 2022 Oct 28 [cited 2024 Apr 11];101(43):e31425–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622663/
[7]. Endo A, Nemoto A, Hanawa K, Maebayashi Y, Hasebe Y, Kobayashi M, et al. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. Journal of Infection and Chemotherapy. 2019 Jan;25(1):17–21.
[8]. Saikumar Matcha, Jayashree Dillibatcha, Arun Prasath Raju, Bhim Bahadur Chaudhari, Sudheer Moorkoth, Lewis LE, et al. Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates. Pediatric Drugs [Internet]. 2023 Mar 21 [cited 2024 Aug 28];25(3):365–75. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097735/
[9].
Siddiqi A, Khan DA, Khan FA, Razzaq A. Therapeutic drug monitoring of amikacin in preterm and term infants. Singapore Medical Journal [Internet]. 2009 May 1;50(5):486–9. Available from:
https://pubmed.ncbi.nlm.nih.gov/19495517/
[10]. Abdel-Hady E, El Hamamsy M, Hedaya M, Awad H. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Journal of Clinical Pharmacy and Therapeutics. 2011 Jan 4;36(1):45–52.
[11]. Hughes KM, Johnson PN, Anderson MP, Sekar KC, Welliver RC, Miller JL. Comparison of Amikacin Pharmacokinetics in Neonates Following Implementation of a New Dosage Protocol. The Journal of Pediatric Pharmacology and Therapeutics : JPPT [Internet]. 2017 ;22(1):33–40. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341529/
[12]. Lulic-Botica M, Sheer T, Edwards D, Thomas RL, Natarajan G. Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates. The Journal of Clinical Pharmacology. 2013 Oct 31;54(1):39–45.
[13]. Schreuder MF, Wilhelm AJ, A. Bokenkamp, Timmermans SMH, de D, J.A.E. van Wijk. Impact of Gestational Age and Birth Weight on Amikacin Clearance on Day 1 of Life. Clinical Journal of the American Society of Nephrology. 2009 Nov 1;4(11):1774–8.
[14]. Langhendries JP, Battisti O, Bertrand JM, François A, Darimont J, Ibrahim S, et al. Once-a-Day Administration of Amikacin in Neonates: Assessment of Nephrotoxicity and Ototoxicity. Developmental Pharmacology and Therapeutics. 1993;20(3-4):220–30.
[15]. Edgar Jake AA, Francisco AV. Assessment of the Ototoxic Effects of Amikacin and Meropenem among Neonates in a Tertiary Government Hospital. Philippine Journal of Otolaryngology-Head and Neck Surgery [Internet]. 2014 Dec 1 [cited 2024];29(2). Available from: https://pjohns.pso-hns.org/index.php/pjohns/article/view/411/1025#info doi:10.32412/pjohns.v29i2.411
[16]. Kotze A, Bartel P, Sommers DK. Once versus twice daily amikacin in neonates: Prospective study on toxicity. Journal of Paediatrics and Child Health. 1999 Jun 1;35(3):283–6
[17]. Nanavati RN, Hakeem MA, Gagtey N, Swar BD. Serum Amikacin Levels And Hearing In Very Low Birth Weight (VLBW) Infants. Journal of Clinical and Diagnostic Research [Internet]. 2010 Oct 12;4:3323–6. Available from: http://www.jcdr.in/article_fulltext.asp?issn=0973- 709x&year=2010&volume=4&issue=6&page=3323-3326&issn=0973-709x&id=822.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medicine & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Engineering Technology (JET) is an open-access journal that follows the Creative Commons Attribution-Non-commercial 4.0 International License (CC BY-NC 4.0)
